精神科藥物交互作用資訊系統
正在載入專業醫療資訊...
精神科藥物與大麻交互作用
專業醫療資訊系統精神科藥物與大麻交互作用概覽
本系統整理了精神科常用藥物與大麻之間的交互作用資訊，提供醫療專業人員參考使用。
73
總藥物數
15
藥物亞類
5
主要類別
4
風險等級
風險等級說明
高風險
避免併用；風險超過效益
中度風險
通常避免併用；僅在特殊情況下使用
低風險
最小化風險；評估風險並考慮替代藥物
資料不足
無足夠交互作用資訊
重要警語
- 本資訊僅供醫療專業人員參考，不應作為醫療診斷或治療的唯一依據
- 使用任何藥物前請諮詢合格醫療專業人員
- 藥物交互作用可能因個體差異而有所不同
- 如發現任何不良反應，請立即停用並就醫
免責聲明
本系統提供的資訊基於現有醫學研究文獻，僅供教育和參考用途。醫療決策應基於個別患者的臨床狀況， 並由合格的醫療專業人員進行評估。本系統不承擔因使用此資訊而產生的任何直接或間接責任。
參考文獻
以下是編制本資訊系統時參考的主要醫學研究文獻和指南。
抗憂鬱藥物交互作用研究
Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.
Geffrey AL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-51.
Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2(1):139-154.
抗精神病藥物研究
Schubart CD, et al. Cannabis use at a young age is associated with psychotic experiences. Psychol Med. 2011;41(6):1301-10.
Marconi A, et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5):1262-9.
鎮靜劑和安眠藥研究
Chesher GB, Jackson DM. The effect of (-)-trans-delta9-tetrahydrocannabinol and its interactions with chlorpromazine and imipramine on the operant behaviour of mice. Psychopharmacologia. 1974;40(4):297-310.
Crippa JA, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417-26.
情緒穩定劑研究
Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020.
Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096.
藥物動力學研究
Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86-95.
Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019;8(7):989.
臨床指南
World Health Organization. CANNABIDIOL (CBD) Critical Review Report. Expert Committee on Drug Dependence Fortieth Meeting. 2018.
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Cannabis Use Disorder. 2021.